Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Regeneron Pharmaceuticals second quarter 2026 earnings conference call. My name is Michelle, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Please note that this conference call is being recorded. I will now just turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin. Thank you, Michelle. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our second quarter 2026 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes. Joining me on today's call are Dr. Leonard Schleifer, co-founder, board, co-chair, president, and chief executive officer, Dr. George Yancopoulos, co-founder, board, co-chair, president, and chief scientific officer, Marion McCourt, Executive Vice President Commercial, and Chris Fenimore, Executive Vice President Finance and Chief Financial Officer. For our call today, Len will briefly review key second quarter performance drivers, highlight important upcoming pipeline catalysts, and provide a few comments on capital allocation. George will then detail our recent pipeline progress, followed by Marion, who will review our commercial portfolio, and finally Chris will discuss our financial results and outlook. After our prepared remarks, the remaining time will be available for Q&A. I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron. Such statements may include but are not limited to those related to Regeneron and its products and business, f...